Elisabeth Bjork heads up AstraZeneca’s late-stage development within cardiovascular, renal and metabolic diseases (CVRM), and is responsible for late-stage clinical development, large outcomes programs, major global filings and health authority interactions (FDA, EMA, Japan, China).
Elisabeth’s focus is to get life-changing medications to patients as early as possible to improve their quality and longevity of life.